Expertise

Services

Solutions

About Us

Resources

Request Quote

  • Home
  • Integrated Proviral DNA, Absolute Answers: TaqMan Absolute Q dPCR for Lentiviral VCN Determination

Integrated Proviral DNA, Absolute Answers: TaqMan Absolute Q dPCR for Lentiviral VCN Determination

Challenge

Lentiviral vectors are widely used for stable gene delivery because they can transduce both dividing and non-dividing cells, enabling long-term transgene expression. But whether you’re running basic research or advancing a cell and gene therapy program, you need a titration method that is precise, reproducible, and transferable—especially when decisions like multiplicity of infection (MOI), dose selection, and product release depend on it.

Traditional qPCR-based lentiviral titration can be slow and calibration-heavy. Accurate quantification typically requires a standard curve built from a control template with a known copy number, and results can be sensitive to amplification efficiency, inhibitors, and operator-to-operator variability. These challenges become more pronounced when sample input is limited or DNA quality is suboptimal.

Solution

To solve this, we implemented a TaqMan-based QuantStudio Absolute Q digital PCR (dPCR) workflow for functional lentiviral titration by measuring integrated proviral DNA in transduced cells. dPCR works by partitioning a sample into thousands of individual PCR microreactions: some contain the target (positive) and others do not (negative). After endpoint amplification, the fraction of negative partitions is used to calculate absolute copy number using Poisson statistics—delivering direct quantification without a standard curve.

The most biologically meaningful readout for
functional lentiviral particles is not simply
“how much viral genome is present,” but how many
proviral DNA copies are integrated per cell—often
reported as vector copy number (VCN). Measuring
VCN provides a direct view of transduction
performance and supports rational selection of MOI
without relying solely on proxy readouts such as
fluorescence.

Our approach combined the strengths of both platforms:

  • qPCR for assay setup and primer/probe optimization We used serial dilutions of known viral DNA to verify TaqMan primer/probe specificity, establish amplification efficiency, and define limit of detection (LOD) and expected Ct values across dilutions. This step builds confidence that the assay chemistry is robust before moving to absolute quantification.
  • Absolute Q dPCR for final copy-number quantification (vector copy number, VCN) We then transferred the optimized assay to the QuantStudio Absolute Q Digital PCR
  • System for absolute quantitation of lentiviral integration. A multiplex TaqMan design was used:

    • Target: Lentivirus proviral DNA (integration marker)
    • Reference gene: RNase P (cellular control for genome equivalents / normalization)

This target + reference strategy supports accurate copies-per-cell calculations and reduces sample-to-sample variability caused by differences in input DNA. Where appropriate, a one-step dPCR workflow (e.g., ViralSEQ dPCR Lentivirus Physical Titer Kit, Thermo Fisher Scientific) can be used to streamline determination of copy number across serial dilutions and confirm the quantitative range.

Why dPCR improves lentiviral titration:

  • Absolute quantification (no standard curve required)
  • Strong performance at low copy number (less variability than qPCR near the lower range)
  • High precision, sensitivity, and reproducibility across runs
  • Better tolerance of challenging sample inputs (low DNA quantity, lower-quality material)

Outcome

We developed a reliable, transferable multiplex TaqMan Absolute Q dPCR assay for lentiviral titration using proviral DNA + RNase P. This workflow delivers endpoint absolute quantification of integrated lentiviral genomes, reducing calibration burden and minimizing susceptibility to run-to-run variation.

By enabling accurate determination of infectious titer, MOI optimization, and vector copy number (VCN), the assay provides critical process and product insights for lentiviral vector manufacturing and gene-modified cell therapy development. These metrics support:

  • Improved control of gene transfer efficiency
  • Better-informed dose selection and MOI setting during transduction
  • Stronger characterization for quality attributes linked to safety and performance

Overall, this case study supports digital PCR (dPCR) as a powerful tool for lentiviral infectious titer and VCN determination, helping advance cell and gene therapy programs targeting diseases such as cancer, HIV, cardiovascular disorders, neurodegenerative diseases, and asthma through more onsistent, data-driven development decisions.

Speak To Our Scientist About Your Multiplex Cytokine Assay, Cytokine Quantification On Meso Scale Discovery

SPEAK TO OUR SCIENTISTS

Similar Case Study Articles